Cipla receives EIR from the FDA for its Indore facility

Cipla receives EIR from the US FDA for its Indore facility


Cipla Limited announced that it has received Establishment Inspection Report (EIR) from the US FDA for its Indore facility indicating formal closure of the US FDA inspection conducted in July/August, 2015.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For over 80 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 100 countries. The Company's portfolio includes over 1000 products across wide range of therapeutic categories with one quality standard globally.

Cipla's research and development focuses on developing innovative products and drug delivery systems.


Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

National Health Policy

Is National Health Policy 2017 helpful for patients?

Send this article by email